Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Munich - Delayed Quote EUR

Halozyme Therapeutics Inc (RV7.MU)

Compare
51.40
+0.08
+(0.16%)
As of 5:27:07 PM GMT+2. Market Open.
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for RV7.MU

Recent News: RV7.MU

View More
If EPS Growth Is Important To You, Halozyme Therapeutics (NASDAQ:HALO) Presents An Opportunity

If EPS Growth Is Important To You, Halozyme Therapeutics (NASDAQ:HALO) Presents An Opportunity
Simply Wall St. yesterday
Biotech Stock Bounces From Support, Shows Relative Strength Amid Volatile Market

Biotech Stock Bounces From Support, Shows Relative Strength Amid Volatile Market
Investor's Business Daily 5 days ago
Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy

Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy
PR Newswire 6 days ago
European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility

European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility
PR Newswire 8 days ago
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
Zacks 9 days ago
European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer
PR Newswire 10 days ago
Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) with ENHANZE® Across Multiple Solid Tumor Indications

Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) with ENHANZE® Across Multiple Solid Tumor Indications
PR Newswire 17 days ago
Why Is Acadia (ACAD) Down 11.1% Since Last Earnings Report?

Why Is Acadia (ACAD) Down 11.1% Since Last Earnings Report?
Zacks 20 days ago
Myriad (MYGN) Down 17.1% Since Last Earnings Report: Can It Rebound?

Myriad (MYGN) Down 17.1% Since Last Earnings Report: Can It Rebound?
Zacks 22 days ago
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Zacks 24 days ago
Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy?

Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy?
Zacks 27 days ago
View More

Related Tickers

CRGX CARGO Therapeutics, Inc.
4.7000
+1.29%
 
COYA Coya Therapeutics, Inc.
5.27
+0.96%
 
GOSS Gossamer Bio, Inc.
0.8367
+0.80%
 
KROS Keros Therapeutics, Inc.
14.13
+4.40%
 
IBRX ImmunityBio, Inc.
2.4854
+0.22%
 
MURA Mural Oncology plc
2.6800
+10.74%
 
NVAX Novavax, Inc.
6.00
-3.31%